Immune Pharmaceuticals Initiates Phase II Studies of Bertilimumab for Ulcerative Colitis and Bullous Pemphigoid

Immune Pharmaceuticals Initiates Phase II Studies of Bertilimumab for Ulcerative Colitis and Bullous Pemphigoid
Immune Pharmaceuticals Inc., a company currently developing novel, highly-targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer, recently announced the initiation of a Phase II Ulcerative Colitis trial and the schedule of the initiation of a Phase II Bullous Pemphigoid trial on July 1, 2015. The initiation of the study allows for

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *